Discover investment opportunities in Theraputic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Theraputic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Theraputic Stocks using our Smart AI Filter.
9 stocks found for "Theraputic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.06 | ±44.4% | -272.1 | 0.00% | |||
0.70 | ±46.8% | 1.5 | 0.00% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.61 | ±31.4% | 19.2 | 0.00% | |||
0.60 | ±39.2% | 20.8 | 0.00% | |||
0.62 | ±41.3% | -11.5 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) compare in terms of growth potential?
A: Vertex Pharmaceuticals (VRTX) focuses on innovative therapies for cystic fibrosis, showing steady revenue growth. Biogen (BIIB) targets neurological disorders but faces challenges in diversifying its portfolio. Investors may find Vertex's pipeline indicates consistent growth, while Biogen's risks are tied to regulatory outcomes.
Q: What factors affect the dividend yield of Gilead Sciences (GILD)?
A: Gilead Sciences (GILD) offers a dividend yield influenced by its cash flow, driven primarily by its HIV and hepatitis drugs. The yield depends on the company's ability to maintain product revenues despite competition and patent expirations.
Q: How might economic downturns impact Regeneron Pharmaceuticals (REGN) stock performance?
A: Regeneron Pharmaceuticals (REGN) tends to be less affected by economic downturns due to its focus on essential treatments like Eylea for vision disorders. Pharmaceutical stocks often exhibit defensive characteristics, providing stability during volatile markets.
Q: What is the competitive advantage of Amgen (AMGN) in the biotechnology sector?
A: Amgen (AMGN) benefits from a strong portfolio of biologics, significant R&D investment, and a leading biosimilars division. Its established market presence and robust pipeline offer competitive advantages in targeting chronic diseases and oncology.
Q: How does Moderna (MRNA) address ESG investing criteria?
A: Moderna (MRNA) emphasizes sustainability through its focus on RNA therapies that may reduce production waste and environmental impact. Their innovative research aligns with social impact ideals but monitoring regulatory compliance and ethical practices remains essential for ESG investors.
Q: What risks do Incyte Corporation (INCY) investors face regarding new drug approvals?
A: Incyte Corporation (INCY) investors face risks related to regulatory oversight and clinical trial success for its pipeline products. Delays or failures in trials can significantly impact stock performance, emphasizing the need for diversification in biotechnology investments.